Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients


Kebapcilar L., Kebapcilar A. G., Bilgir O., Taner C. E., Bozkaya G., Yildiz Y., ...More

GYNECOLOGICAL ENDOCRINOLOGY, vol.27, no.2, pp.91-95, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 2
  • Publication Date: 2011
  • Doi Number: 10.3109/09513590.2010.491164
  • Journal Name: GYNECOLOGICAL ENDOCRINOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.91-95
  • Keywords: sCD40L, metformin, ethinyl oestradiol plus cyproterone acetate, PCOS, POLYCYSTIC-OVARY-SYNDROME, ACTIVATABLE FIBRINOLYSIS INHIBITOR, CARDIOVASCULAR RISK-FACTORS, FACTOR-KAPPA-B, POSTMENOPAUSAL WOMEN, NUCLEAR-FACTOR, ENDOTHELIAL-CELLS, CD40 LIGAND, DISEASE, ATHEROSCLEROSIS
  • Dokuz Eylül University Affiliated: Yes

Abstract

Methods. Total of 60 patients with PCOS was studied to evaluate and compare with a non-PCOS group consisting of 30 subjects. A low-dose oral contraceptive containing ethinyl oestradiol-cyproterone acetate (EE/CA) and metformin (M; 850 mg metformin twice a day) were given for three cycles. Plasma sCD40L was measured before and after the treatment of 3 months.